Selected Drugs Clear All
MultiCheck Results
- 16
Interactions
Monitor/Modify Tx |
||
|
Corynanthe johimbe
(yohimbe (Pausinystalia yohimbe)) + Excedrin Migraine
(acetaminophen/ aspirin/ caffeine) |
||
Monitor/Modify Txyohimbe + caffeine monitor BP, HR; avoid excessive caffeine intake: combo may incr. risk of HTN, tachycardia (additive effects) |
||
|
Corynanthe johimbe
(yohimbe (Pausinystalia yohimbe)) + Nextstellis
(drospirenone/ estetrol) |
||
Monitor/Modify Txyohimbe + estetrol (contraceptive) monitor BP: combo may incr. risk of HTN (additive effects) |
||
|
Corynanthe johimbe
(yohimbe (Pausinystalia yohimbe)) + Votrient
(pazopanib) |
||
Monitor/Modify Txyohimbe + pazopanib monitor BP: combo may incr. risk of HTN (additive effects) |
||
|
Excedrin Migraine
(acetaminophen/ aspirin/ caffeine) + Janumet XR
(sitagliptin/ metformin) |
||
Monitor/Modify Txaspirin + sitagliptin monitor renal fxn, glucose, especially w/ high-dose aspirin: combo may incr. risk of nephrotoxicity, hypoglycemia (additive effects) |
||
|
Excedrin Migraine
(acetaminophen/ aspirin/ caffeine) + Nextstellis
(drospirenone/ estetrol) |
||
Monitor/Modify Txcaffeine + estetrol (contraceptive) monitor BP; avoid excessive caffeine intake: combo may incr. risk of HTN (additive effects) |
||
|
Excedrin Migraine
(acetaminophen/ aspirin/ caffeine) + Votrient
(pazopanib) |
||
Monitor/Modify Txaspirin + pazopanib monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects) caffeine + pazopanib monitor BP; avoid excessive caffeine intake: combo may incr. risk of HTN (additive effects) |
||
|
Janumet XR
(sitagliptin/ metformin) + Nextstellis
(drospirenone/ estetrol) |
||
Monitor/Modify Txmetformin + drospirenone (contraceptive) monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects) metformin + estetrol (contraceptive) monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects) sitagliptin + drospirenone (contraceptive) monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects) sitagliptin + estetrol (contraceptive) monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects) |
||
|
Janumet XR
(sitagliptin/ metformin) + Psorcon E
(diflorasone topical) |
||
Monitor/Modify Txmetformin + diflorasone topical monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects) sitagliptin + diflorasone topical monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects) |
||
|
Janumet XR
(sitagliptin/ metformin) + Votrient
(pazopanib) |
||
Monitor/Modify Txsitagliptin + pazopanib monitor renal, cardiac fxn: combo may incr. risk of nephrotoxicity, cardiotoxicity (additive effects) |
||
|
Nextstellis
(drospirenone/ estetrol) + Votrient
(pazopanib) |
||
Monitor/Modify Txdrospirenone (contraceptive) + pazopanib monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects) estetrol (contraceptive) + pazopanib monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects) |
||
Additional Considerations |
||
|
yohimbe
in Corynanthe johimbe
|
||
|
yohimbe products may contain varying amounts of yohimbine, other alkaloids |
||